Overview

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Status:
Active, not recruiting

Trial end date:
2025-01-15

Target enrollment:

Participant gender:

Summary

This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Huazhong University of Science and Technology

Collaborator:

Shiyan Taihe Hospital